We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+17.27%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.99B
AUM Growth
+$232M
Cap. Flow
+$64.9M
Cap. Flow %
3.27%
Top 10 Hldgs %
47.8%
Holding
194
New
23
Increased
33
Reduced
38
Closed
65
Avg Time Held Equity + Options
4.7 quarters
Top 10 Avg Time Held Equity + Options
5.1 quarters
Top 20 Avg Time Held Equity + Options
6.3 quarters
Avg Time Held Equity only
4.9 quarters
Top 10 Avg Time Held Equity only
5.1 quarters
Top 20 Avg Time Held Equity only
6.4 quarters

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$46.6M
2
PBYI icon
Puma Biotechnology
PBYI
+$41M
3
DOVA
Dova Pharmaceuticals, Inc. Common Stock
DOVA
+$35.9M
4
CORI
Corium International, Inc.
CORI
+$19M
5
ISRG icon
Intuitive Surgical
ISRG
+$17.9M

Top Sells

Rank Stock Value
1
ACRS icon
Aclaris Therapeutics
ACRS
+$37.6M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$22.2M
3
NVRO icon
NEVRO CORP.
NVRO
+$20.4M
4
AVXS
AveXis, Inc. Common Stock
AVXS
+$13.3M
5
AMAG
AMAG Pharmaceuticals
AMAG
+$12.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.26%
2 Miscellaneous 3.45%
3 Consumer Staples 0.19%
4 Consumer Discretionary 0.06%
5 Energy 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ABEO icon
76
Abeona Therapeutics
ABEO
$280M
$2.71M 0.14%
16,915
-8,000
-32% -$1.09M
2014 Q4
10 quarters
OCRX
77
DELISTED
Ocera Therapeutics, Inc.
OCRX
$2.37M 0.12%
2,038,880
-111,120
-5% -$129K
2017 Q1
1 quarter
VRNA
78
DELISTED
Verona Pharma
VRNA
$2.33M 0.12%
+200,000
New +$2.65M
2017 Q2
0 quarters
XENE icon
79
Xenon Pharmaceuticals
XENE
$3.47B
$2.28M 0.11%
723,853
– –
2014 Q4
10 quarters
MGCD
80
DELISTED
MGC Diagnostics Corporation
MGCD
$2.14M 0.11%
252,327
-50,000
-17% -$411K
2013 Q2
16 quarters
BLUE icon
81
DELISTED
bluebird bio
BLUE
$2.1M 0.11%
1,544
+1,185
+330% +$1.43M
2017 Q1
1 quarter
DMK
82
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
$2.08M 0.1%
+5,714
New +$1.71M
2017 Q2
0 quarters
EYPT icon
83
EyePoint Inc
EYPT
$286M
$1.97M 0.1%
114,956
-113,015
-50% -$2.15M
2014 Q4
10 quarters
CRIS icon
84
Curis
CRIS
$1.56M
$1.8M 0.09%
476
+226
+90% +$944K
2017 Q1
1 quarter
BCLI icon
85
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$1.66M 0.08%
+26,667
New +$1.64M
2017 Q2
0 quarters
ADYX
86
DELISTED
Adynxx Inc
ADYX
$1.57M 0.08%
70,566
– –
2014 Q4
10 quarters
TVRD icon
87
CALL
Tvardi Therapeutics
TVRD
$14.1M
$1.54M 0.08%
+2,778
New +$1.76M
2017 Q2
0 quarters
ARWR icon
88
Arrowhead Research
ARWR
$8.58B
$1.37M 0.07%
847,458
– –
2016 Q3
3 quarters
AFMD icon
89
DELISTED
Affimed
AFMD
$1.37M 0.07%
66,821
-6,609
-9% -$147K
2016 Q2
4 quarters
EIGR
90
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$1.25M 0.06%
5,256
– –
2016 Q1
5 quarters
EXEL icon
91
Exelixis
EXEL
$14.8B
$1.14M 0.06%
46,361
– –
2016 Q4
2 quarters
LNTH icon
92
Lantheus
LNTH
$6.54B
$949K 0.05%
53,763
– –
2016 Q3
3 quarters
OSUR icon
93
OraSure Technologies
OSUR
$270M
$945K 0.05%
54,729
+7,604
+16% +$109K
2017 Q1
1 quarter
CSBR icon
94
Champions Oncology
CSBR
$68.9M
$943K 0.05%
366,973
+1
+0% +$3
2015 Q3
7 quarters
GRDX icon
95
GridAI Technologies Corp
GRDX
$33.2M
$916K 0.05%
2
– –
2016 Q4
2 quarters
WCG
96
DELISTED
Wellcare Health Plans, Inc.
WCG
$908K 0.05%
5,056
-227
-4% -$37.6K
2016 Q1
5 quarters
OTLK icon
97
Outlook Therapeutics
OTLK
$142M
$837K 0.04%
5,237
-2,150
-29% -$607K
2016 Q2
4 quarters
HSKA
98
DELISTED
Heska Corp
HSKA
$745K 0.04%
7,300
+1,000
+16% +$98.7K
2017 Q1
1 quarter
OXFD
99
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$741K 0.04%
+44,106
New +$659K
2017 Q2
0 quarters
LHCG
100
DELISTED
LHC Group LLC
LHCG
$728K 0.04%
10,730
+5,985
+126% +$357K
2016 Q3
3 quarters
2 3
4
5 6

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q2 2017 Portfolio in Review

As of Q2 2017, Perceptive Advisors held 194 positions worth $1.99B, up 13% from $1.76B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Perceptive Advisors deployed $64.9M of net new capital in Q2 2017, opening 23 new positions and adding to 33 existing holdings. Its largest new stake was Puma Biotechnology: 733,320 shares worth $64.1M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 98% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $22.2M trimmed.

  • Perceptive Advisors's largest Q2 2017 buy was Puma Biotechnology: 733,320 shares worth $64.1M.
  • Perceptive Advisors added most to Alnylam Pharmaceuticals in Q2 2017, an estimated $46.6M increase.
  • Perceptive Advisors's biggest Q2 2017 reduction was Sarepta Therapeutics, cutting an estimated $22.2M.
  • Perceptive Advisors fully exited Aclaris Therapeutics in Q2 2017, selling an estimated $37.6M.
  • Perceptive Advisors's ten largest holdings make up 48% of its $1.99B portfolio in Q2 2017.
  • Perceptive Advisors opened 23 new positions and closed 65 in Q2 2017.
  • Perceptive Advisors's portfolio value rose 13% quarter-over-quarter to $1.99B.

Based on Perceptive Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.